TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05646771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner support
Description: Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
Study: NCT05781399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Suspension
Description: JNT-517 in on-site compounded suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Suspension
Description: JNT-517 in on-site compounded suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Suspension
Description: JNT-517 in on-site compounded suspension
Study: NCT05358535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Study: NCT06209086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletal anchored twin block
Description: This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletal anchored twin block
Description: This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally.
Study: NCT05708235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an orally administered CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
Study: NCT04213274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 80 mg RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 80 mg RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 80 mg RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Study: NCT05791149

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva tube
Description: 1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: saliva tube
Description: 1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
Study: NCT04593329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIRADENTES ASSOCIATION
Description: Tiradentes association tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE
Description: Dipyrone 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL
Description: Tramadol 50 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TIRADENTES ASSOCIATION PLACEBO
Description: Tiradentes association placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TIRADENTES ASSOCIATION PLACEBO
Description: Tiradentes association placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIPYRONE PLACEBO
Description: Dipyrone placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE PLACEBO
Description: Dipyrone placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL PLACEBO
Description: Tramadol placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAMADOL PLACEBO
Description: Tramadol placebo capsule
Study: NCT05781399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Suspension
Description: JNT-517 in on-site compounded suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Suspension
Description: JNT-517 in on-site compounded suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Suspension
Description: On-site compounded placebo suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Suspension
Description: On-site compounded placebo suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517 tablets, 25 mg and 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517 tablets, 25 mg and 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517 tablets, 25 mg and 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517 tablets, 25 mg and 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Matching film-coated placebo tablet
Study: NCT05721625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
Study: NCT06363617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLI
Description: Health professionals will use the FLI test in their clinical practice
Study: NCT04800718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
Study: NCT06404463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
Study: NCT06285695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Toric IOL
Description: Aspheric hydrophobic acrylic IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery for the visual correction of aphakia and preexisting corneal astigmatism
Study: NCT05598827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tik Tok
Description: The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
Study: NCT05323565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: adjuvants to 0.25 bupivacaine in TAB block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: adjuvants to 0.25 bupivacaine in TAB block.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: adjuvants to 0.25 bupivacaine in TAB block.
Study: NCT05637658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise
Study: NCT05721625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
Study: NCT05978895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted canteen menus
Description: The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population.
Study: NCT06404463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
Study: NCT06285695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation with a Clareon Toric IOL
Study: NCT05644184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
Study: NCT04877223

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05644184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
Study: NCT05908318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory training
Description: In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
Study: NCT05644184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
Description: The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Study: NCT05973396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Fatiguing Task only
Description: Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and Mental Fatiguing Task
Description: Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
Study: NCT05436366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus loading response in able-bodied participants
Description: Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus loading response in participants with hemiparesis
Description: Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
Study: NCT04748588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 mAb
Description: Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used.